Benjamin F. Edwards & Company, Inc. Axogen, Inc. Transaction History
Benjamin F. Edwards & Company, Inc.
- $5.69 Billion
- Q2 2024
A detailed history of Benjamin F. Edwards & Company, Inc. transactions in Axogen, Inc. stock. As of the latest transaction made, Benjamin F. Edwards & Company, Inc. holds 200 shares of AXGN stock, worth $3,128. This represents 0.0% of its overall portfolio holdings.
Number of Shares
200
Previous 200
-0.0%
Holding current value
$3,128
Previous $2,000
50.0%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding AXGN
# of Institutions
162Shares Held
36.6MCall Options Held
230KPut Options Held
400-
First Light Asset Management, LLC Edina, MN4.09MShares$64 Million5.0% of portfolio
-
Black Rock Inc. New York, NY3.25MShares$50.8 Million0.0% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT3.01MShares$47 Million3.58% of portfolio
-
Morgan Stanley New York, NY2.9MShares$45.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.43MShares$37.9 Million0.0% of portfolio
About Axogen, Inc.
- Ticker AXGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 42,283,700
- Market Cap $661M
- Description
- AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgic...